Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Average (2016 - 2025)

Historic Equity Average for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $80.2 million.

  • Ultragenyx Pharmaceutical's Equity Average fell 7941.02% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year decrease of 7941.02%. This contributed to the annual value of $265.4 million for FY2024, which is 1547.95% down from last year.
  • Ultragenyx Pharmaceutical's Equity Average amounted to $80.2 million in Q3 2025, which was down 7941.02% from $147.8 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Equity Average ranged from a high of $1.1 billion in Q1 2021 and a low of $80.2 million during Q3 2025
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Equity Average value was $301.1 million (recorded in 2024), while the average stood at $467.8 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Equity Average crashed by 8598.45% in 2023, and later surged by 38477.39% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Equity Average stood at $928.1 million in 2021, then crashed by 55.75% to $410.7 million in 2022, then tumbled by 62.61% to $153.6 million in 2023, then soared by 96.05% to $301.1 million in 2024, then tumbled by 73.35% to $80.2 million in 2025.
  • Its Equity Average was $80.2 million in Q3 2025, compared to $147.8 million in Q2 2025 and $199.8 million in Q1 2025.